ISB News

New Publication in ‘Cancer Cell’

As part of The Cancer Genome Atlas project, the Shmuelvich Lab and colleagues published a paper in the journal Cancer Cell related to the rare cancer adrenocortical carcinoma. Read the summary:

3 Bullets:

  • Adrenocortical carcinoma (ACC) is a rare, under-researched endocrine cancer with limited therapeutic options and overall poor outcome.
  • TCGA researchers performed comprehensive analysis of 91 ACC samples to gain better understanding of potential genetic causes of the cancer.
  • Researchers revealed whole genome doubling as a milestone in disease progression and discovered a potential biomarker that is based on DNA methylation that may inform ACC drug therapies.

By Varsha Dhankani

Adrenocortical carcinoma (ACC) is a rare endocrine cancer with limited therapeutic options and overall poor outcome. In TCGA (The Cancer Genome Atlas) research published on May 9, 2016, in the journal Cancer Cell, scientists, including several from Institute for Systems Biology, comprehensively analyzed 91 ACC specimens from four continents using state-of-the-art genomic technologies and computational methods. The goal of the study was to identify additional oncogenic alterations to provide a framework for further research and guide development of therapies. READ MORE…

Related Articles

  • Dr. Wei Wei Awarded CARE Grant

    The Andy Hill Cancer Research Endowment (CARE) is a public-private partnership that supports cancer research in Washington state. CARE announced ISB Assistant Professor Dr. Wei Wei as a CARE Fund Distinguished Researcher and awarded him $500,000.

    Read More
  • ISB's Dr. Sui Huang Earns Funding to Tackle Cancer's Biggest Questions

    ISB’s Professor Sui Huang, MD, PhD, has been announced by Cancer Research UK as a member of a global research team funded through its Grand Challenge competition — an international funding initiative that aims to answer some of the biggest questions facing cancer research.

    Read More
  • ISB President Dr. Jim Heath

    ISB President Dr. Jim Heath Awarded $750,000 from Andy Hill Cancer Research Endowment

    The Andy Hill Cancer Research Endowment (CARE) announced $750,000 in grant funding for Dr. Jim Heath’s work on proactive cancer immunotherapies for initial and recurrent disease. This is the first stage of a planned longer program led by Jim and ISB, and involving Swedish Cancer Institute, Earl A. Chiles Research Institute in Portland, and UW Medicine.

    Read More
Show More Articles